Quality of Life in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis
DATE
DATE Trial: Outcomes and Quality of Life in Patients With Early Versus Elective Resection in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis
1 other identifier
interventional
136
2 countries
4
Brief Summary
Patients presenting in hospital with symptoms of acute diverticulitis. Acute inflammation of the left-sided colon is confirmed with CT scan or ultrasound in experienced centers and diagnosis is defined according to the "Classification of Diverticular Disease (CDD)". CDD Type 2a, 2b and 3b will be included and then randomized in two groups. Group A will get an early left hemicolectomy 7 to 10 days after admission and initial antibiotic therapy and/or drainage of the abscess. Group B is designated for an elective resection 6 to 8 weeks after dismissal at the earliest and initial conservative treatment and/or after drainage of the abscess. Six weeks after the operation patients of Group A will be asked for their present quality of life with a standardized scoring system (Gastrointestinal Quality of Life Index = GIQLI; Short-form 36 Score = SF-36 Score; Low anterior resection syndrome = LARS Score). Group B (elective resection) will be asked at their readmission prior to elective surgery is done. This survey package will be repeated again 6 to 8 weeks later in both groups. Primary endpoints will be the two GIQLI at the said examination times. Secondary endpoints will be SF-36 score, LARS-score, GIQLI-Domains, anastomosis insufficiency and other complications, mortality and length of hospital stay. Comparisons between the groups are made at the said examination times but also 6-8 weeks after the operation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2023
Longer than P75 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 16, 2023
CompletedFirst Submitted
Initial submission to the registry
June 7, 2023
CompletedFirst Posted
Study publicly available on registry
July 12, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
March 18, 2026
March 1, 2026
3.9 years
June 7, 2023
March 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Gastrointestinal Quality of Life Index
Quality of Life
Up to 18 weeks
Secondary Outcomes (8)
SF-36 score (Short form score)
Up to 18 weeks
Low anterior resection syndrome score
Up to 18 weeks
Anastomosis insufficiency
Up to 18 weeks
Intraoperative complication
Up to 18 weeks
Exitus
Up to 18 weeks
- +3 more secondary outcomes
Study Arms (2)
Group A (Early)
EXPERIMENTALEarly left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
Group B (Late)
OTHERElective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
Interventions
Eligibility Criteria
You may qualify if:
- Informed consent to participate in the study
- CDD Type 2a, 2b: acute complicated left-sided diverticulitis
- CDD Type 3b: relapsing diverticulitis without complications (\>2 episodes within 2 years)
- Acute presentation
- Inflammation located in the left-sided colon
- Inflammation is CT proven or ultrasound confirmed from experienced radiologists
You may not qualify if:
- \< 18 years
- Pregnancy
- BMI \> 55kg/m2
- Current colorectal carcinoma in the left-sided colon
- Oral and/or intravenous corticosteroid
- Ongoing chemotherapy
- Status post left hemicolectomy
- Patients who cannot take care of themselves at home or are unable to follow instructions
- Patients who are not fit for surgery (anesthesia, expert knowledge from specialists) and will not benefit from surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Elisabethinen Hospitalcollaborator
- Universitätsmedizin Mannheimcollaborator
- Kepler University Hospitallead
- Krankenhaus Barmherzige Schwestern Linzcollaborator
Study Sites (4)
Ordensklinikum Elisabethinen Linz
Linz, Austria, 4020, Austria
Krankenhaus Barmherzige Schwestern Linz
Linz, Upper Austria, 4010, Austria
Kepler University Hospital
Linz, Upper Austria, 4020, Austria
Universitätsklinikum Mannheim
Mannheim, Mannheim, 68167, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andreas Shamiyeh, Dr.
Kepler University Hospital Linz
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2023
First Posted
July 12, 2023
Study Start
January 16, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
July 1, 2027
Last Updated
March 18, 2026
Record last verified: 2026-03